Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06828731 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

A Phase 1 study of PreDiabetes, sponsored by Charles George VA Medical Center.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT06828731: Completed Phase 1 study of PreDiabetes, sponsored by Charles George VA Medical Center.

NCT06828731 is a Phase 1 study of PreDiabetes that has completed, run by Charles George VA Medical Center. The registered enrollment target is 60 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06828731, a Phase 1 study of PreDiabetes, has completed, sponsored by Charles George VA Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.

Primary Outcome

Number of participants screened during study period Number of participants randomized during study period Number of participants enrolled during study period

Conditions Studied

Interventions

  • DRUG Empagliflozin 10mg daily
  • OTHER Lifestyle education

Study Locations (1)

North Carolina

  • Charles George VA Medical Center - Asheville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-12-06
Est. Completion 2025-09-05
Phase Phase 1
Charles George VA Medical Center

1 total trials

What the finished NCT06828731 record still lists

NCT06828731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower).

The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin 10mg daily is the first listed.

NCT06828731 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06828731 about?

NCT06828731 is a clinical study titled "Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes". Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular event...

What is the current status of trial NCT06828731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-12-06. Estimated completion is 2025-09-05.

What conditions does trial NCT06828731 study?

This clinical trial studies the following conditions: PreDiabetes.

What interventions are being tested in trial NCT06828731?

The interventions under investigation include: Empagliflozin 10mg daily (DRUG), Lifestyle education (OTHER).

Who is sponsoring clinical trial NCT06828731?

This trial is sponsored by Charles George VA Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06828731 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PreDiabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06828731's enrollment target sits among peer trials

60 90th of 149 higher than 54 of 149 other PreDiabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06828731, the US trial registry maintained by the National Library of Medicine. NCT06828731 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.